drugset / Trial / NCT00626210

Modafinil Treatment for Sleep/Wake Disturbances in Older Adults

NCT00626210

Phase 4 Terminated 2 enrolled VA Palo Alto Health Care System
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Modafinil, trade named Provigil, is a medication approved by the Food and Drug Administration for the treatment of narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. Each of these problems is characterized by difficulty sleeping at night and excessive daytime sleepiness. Modafinil is prescribed during the day to counteract this sleepiness. The idea behind this treatment is that sleepiness that leads to napping during the day prevents a patient from being tired or sleepy enough to get good sleep at night. This study is designed to determine if the medication can "reset" participants' sleep/wake rhythm to a more normal rhythm.

Timeline

Start
2008-02
Primary completion
2011-04
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Modafinil Small molecule 100 mg
Subject Modafinil Small molecule 400 mg